

Special Issue

Understanding Metabolic-Associated Fatty Liver Disease: Insights into Mechanisms and Management

Message from the Guest Editors

This Special Issue aims to collect the latest research on the pathogenesis and therapeutic approach of MAFLD. We will focus on new pathogenic factors, metabolites, signaling pathways, metabolic regulation, potential drug targets and novel therapeutic drugs for MAFLD. In this Special Issue, we welcome original research and review manuscripts on any aspect of mechanisms of MAFLD, including but not limited to steatosis, oxidative stress, mitochondrial dysfunction, endoplasmic reticulum stress, inflammation, apoptosis, pyroptosis, gut microbiota disorder and metabolic regulation. In addition, studies on therapeutic approaches and drugs for MAFLD, including traditional Chinese medicine, natural product, and food supplement, are also welcome. Altogether, this collection will provide a platform for better understanding the mechanisms of MAFLD and developing a novel therapeutic approach.

Guest Editors

Dr. Jingda Li


College of Life Science, Yangtze University, Jingzhou 434023, China

Dr. Wenlong Sun

School of Life Sciences and Medicine, Shandong University of Technology, Zibo 255049, China

Deadline for manuscript submissions

closed (30 June 2025)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.1
Indexed in PubMed



mdpi.com/si/216672

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.1
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2025).